Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:2157-2164
Published online before print April 25, 2005, doi: 10.1161/01.CIR.0000163562.82134.8E
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/17/2157    most recent
01.CIR.0000163562.82134.8Ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katada, J.
Right arrow Articles by Yoshikawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katada, J.
Right arrow Articles by Yoshikawa, T.
Related Collections
Right arrow Other myocardial biology
Right arrow Other heart failure
Right arrow Remodeling

(Circulation. 2005;111:2157-2164.)
© 2005 American Heart Association, Inc.


Coronary Heart Disease

Persistent Cardiac Aldosterone Synthesis in Angiotensin II Type 1A Receptor–Knockout Mice After Myocardial Infarction

Jun Katada, PhD; Tomomi Meguro, MD; Hitomi Saito, BSc; Akira Ohashi, MD; Toshihisa Anzai, MD; Satoshi Ogawa, MD; Tsutomu Yoshikawa, MD

From the Pfizer-KEIO Research Laboratory (J.K., T.M., H.S., A.O.) and Cardiopulmonary Division, Keio University School of Medicine (S.O., T.A., T.Y.), Tokyo, Japan.

Correspondence to Jun Katada, PhD, Research Park 2N4, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail katada{at}kt.rim.or.jp

Received July 2, 2004; revision received December 16, 2004; accepted December 21, 2004.

Background— The renin-angiotensin-aldosterone system is implicated in the pathogenesis of heart failure. Pharmacological blockade of angiotensin II (Ang II)–dependent signaling is clinically effective in reducing cardiovascular events after myocardial infarction (MI) but still fails to completely prevent remodeling. The molecular basis underlying this Ang II–independent remodeling is unclear.

Methods and Results— Acute MI was induced by coronary ligation in wild-type (WT) and angiotensin II type IA receptor–knockout (AT1A-KO) mice. Left ventricular (LV) geometry, hemodynamics, and cardiac gene expression were evaluated on day 28. Severe LV remodeling and resultant cardiac dysfunction were observed in WT mice, whereas less marked, but still significant, LV remodeling and cardiac dysfunction were induced in AT1A-KO mice. Gene expression levels of aldosterone synthase and the cardiac aldosterone content were both elevated in the MI hearts, even in AT1A-KO mice. In AT1A-KO mice treated with spironolactone (20 mg/kg per day), LV remodeling, cardiac dysfunction, and cardiac gene expression of collagens and natriuretic peptides were almost normalized.

Conclusions— Our results indicate that genetic blockade of AT1A signaling fails to arrest aldosterone production in cardiac tissues and that cardiac aldosterone plays a critical role in post-MI LV remodeling. The results suggest that spironolactone could be potentially effective in patients with MI, when used in combination with renin-angiotensin system blockade, by blocking the actions of aldosterone produced by Ang II–independent mechanisms.


Key Words: myocardial infarction • remodeling • angiotensin




This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Tsukashita, A. Marui, T. Nishina, E. Yoshikawa, H. Kanemitsu, J. Wang, T. Ikeda, and M. Komeda
Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery
J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 58 - 64.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler
Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. Hunyady and K. J. Catt
Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II
Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. Chai, I. M. Garrelds, R. de Vries, and A.H. Jan Danser
Cardioprotective Effects of Eplerenone in the Rat Heart: Interaction With Locally Synthesized or Blood-Derived Aldosterone?
Hypertension, April 1, 2006; 47(4): 665 - 670.
[Abstract] [Full Text] [PDF]